CERo Therapeutics Holdings, Inc. (CERO)
After hours:
- ACCESSWIRE
Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy
VANCOUVER, BC / ACCESSWIRE / June 6, 2024 / Cancer treatments have come a long way over the years, but there is a newer treatment that is providing even stage four cancer patients with a new lease on life. Source: PexelsThe first CAR T-cell therapy ...
- GlobeNewswire
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces the successful completion of toxicology studies for its lead compound, CER-1236. The toxicology studies w
- GlobeNewswire
CERo Therapeutics, Inc. Provides Corporate Update for Shareholders
SOUTH SAN FRANCISCO, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq:CERO) (“CERo”) an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides shareholders with a corporate update reviewing activities since its entering the public market. CERo Chairman and CEO Brian G. Atwood comments, “CERo has undergone significant transformation since the founding of this small priv
